SANA Stock Analysis: Sana Biotechnology | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 882m USD | 12M Return: -27.2% | US7995661045 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 11.3M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 5.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Sana Biotechnology (NASDAQ: SANA) is a Seattle-based clinical-stage biotechnology company developing engineered cell therapies, with operations focused in the United States. The company works across both ex vivo and in vivo cell engineering platforms, targeting areas of unmet need such as type 1 diabetes, B cell mediated autoimmune diseases, and oncology. Its pipeline includes UP421 (a HIP-modified allogeneic islet cell therapy in Phase 1 for type 1 diabetes), SC451 (a stem cell-derived pancreatic islet cell therapy in preclinical development), and the SG293/SG299 fusosome candidates aimed at B cell hematologic malignancies and autoimmune indications.
Sanas business model relies on a combination of internal R&D and external partnerships to advance its pipeline, including an option and license agreement with Beam Therapeutics for CRISPR Cas12b editing technology, a license agreement with Harvard College for hypoimmune-modified cell IP, and a strategic collaboration with Mayo Clinic supporting the SC451 program. Originally incorporated in 2018 as FD Therapeutics, the company rebranded later that year and went public on NASDAQ in early 2021. As a small-cap, pre-revenue biotech in the cell therapy subsector, Sana depends on capital markets and collaboration income to fund its multi-year clinical development activities.
- UP421 phase 1 diabetes trial data readout expected
- Cash runway concerns as R&D spending exceeds $500M annually
- Beam Therapeutics partnership advances gene-edited cell therapy pipeline
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.31 > 0.02 and ΔFCF/TA 19.94 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.31 > 3% & CFO -132.2m > Net Income -211.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (295.7m) vs 12m ago 24.02% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 4.23%; Δ -4.23% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.11 (Total Current Assets 170.6m - Total Current Liabilities 123.8m) / Total Assets 431.5m |
| B: -4.54 (Retained Earnings -1.96b / Total Assets 431.5m) |
| C: -0.53 (EBIT TTM -211.8m / Avg Total Assets 396.6m) |
| D: 0.56 (Book Value of Equity 154.6m / Total Liabilities 277.0m) |
| Altman-Z'' = -17.10 = D |
As of October 04, 2026, the stock is trading at USD 2.89 with a total of 3,495,169 shares traded. Over the past week, the price has changed by -1.87%, over one month by -25.71%, over three months by -27.93% and over the past year by -27.20%.
Current recommended Stop Loss: 2.60 (which is 10% or 1.4 ATR below the current price).
Sana Biotechnology has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy SANA.
- StrongBuy: 4
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 8.4 | 191.7% |
P/B = 5.9652
Revenue TTM = 0.0 USD
EBIT TTM = -211.8m USD
EBITDA TTM = -201.0m USD
Long Term Debt = 59.2m USD (estimated: total debt 73.7m - short term 14.5m)
Short Term Debt = 14.5m USD (from shortTermDebt, last quarter)
Debt = 73.7m USD (from shortLongTermDebtTotal, last quarter) (leases 73.7m already included)
Net Debt = -86.8m USD (calculated: Debt 73.7m - CCE 160.5m)
Enterprise Value = 794.9m USD (881.6m + Debt 73.7m - CCE 160.5m)
Interest Coverage Ratio = unknown (Ebit TTM -211.8m / Interest Expense TTM 0.0)
EV/FCF = -5.89x (Enterprise Value 794.9m / FCF TTM -135.1m)
FCF Yield = -16.99% (FCF TTM -135.1m / Enterprise Value 794.9m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 12.8m) / Revenue TTM)
Tobins Q-Ratio = 1.84 (Enterprise Value 794.9m / Total Assets 431.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 73.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -167.3m (EBIT -211.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.38 (Total Current Assets 170.6m / Total Current Liabilities 123.8m)
Debt / Equity = 0.48 (Debt 73.7m / totalStockholderEquity, last quarter 154.6m)
Debt / EBITDA = 0.43 (negative EBITDA) (Net Debt -86.8m / EBITDA -201.0m)
Debt / FCF = 0.64 (negative FCF - burning cash) (Net Debt -86.8m / FCF TTM -135.1m)
Total Stockholder Equity = 157.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -53.41% (Net Income -211.8m / Total Assets 431.5m)
RoE = -134.5% (Net Income TTM -211.8m / Total Stockholder Equity 157.5m)
RoCE = -97.73% (EBIT -211.8m / Capital Employed (Equity 157.5m + L.T.Debt 59.2m))
RoIC = -51.92% (negative operating profit) (NOPAT -167.3m / Invested Capital 322.3m)
WACC = 11.99% (E(881.6m)/V(955.4m) * Re(12.99%) + D(73.7m)/V(955.4m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.99% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.53 | Cagr: 14.67%
[DCF] Fair Price = unknown (Cash Flow -135.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.51 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.13 | Chg30d=-9.79% | Revisions=+17% | Analysts=4
EPS current Year (2026-12-31): EPS=-0.59 | Chg30d=-2.00% | Revisions=+0% | GrowthEPS=+11.8% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.56 | Chg30d=-6.28% | Revisions=+0% | GrowthEPS=+6.1% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +8% (up=5, down=4)